At Novartis, we have a long-standing history in addressing global health challenges. Over the past 20 years, our approach has evolved from purely donation-based toward models with more sustainable social impact. Today, we apply our expertise and full organizational capability to address major, unresolved global health challenges.
Global Health Flagship Programs
We aim to adopt an integrated end-to-end approach to disease management for the elimination or control of four diseases where there has been market failure and little investment in research and development.
Sickle cell disease (SCD)
Novartis is pursuing a comprehensive approach to tackling SCD. We are developing innovative new medicines to treat it and are working to expand access to diagnosis, treatment and care.
Expanding Access to Healthcare
The work of our Global Health Flagship Programs is closely aligned with our overall efforts to expand access to healthcare for lower-income populations – shifting the focus from neglected diseases to neglected patient populations. With the Novartis access principles, we committed to systematically integrate access strategies into how we research, develop and deliver our new medicines globally.
The Novartis Foundation aims to improve the health of low-income populations by working with local authorities and partners to re-engineer health systems from being reactive to proactive predictive and preventative. Furthermore, the Novartis Foundation focuses on how data, digital and artificial intelligence can transform global health.